The Roche Company Product Information, Ancobon®, September, 1971.
2.
American Hospital Formulary Service, American Society of Hospital Pharmacists, Washington, D.C., 8.12.04.
3.
DrouhtE.: Mechanism of Antifungal Chemotherapy, Modern Treatment7: 539–569, 1970.
4.
ShadomyS.: Further In Vitro Studies with 5-Fluorocytosine, Infections and Immunity2: 484–488, 1970.
5.
ShadomyS.: In Vitro Studies With 5-Fluorocytosine, Applied Microbiol.17: 871–877, 1969.
6.
GrunbergE.: Chemotherapeutic Activity of 5-Fluorocytosine, Antimicrob. Agents Chemother., 566–568, 1963.
7.
ChaubeS., MurphyM. L.: The Teratogenic Effects of 5-Fluorocytosine in the Rat, Cancer Research29: 554–557, 1969.
8.
ToalaE.: Candida at Boston City Hospital, Arch, intern. Med.126: 983–989, 1970.
9.
GoodmanL. S., and GilmanA.: The Pharmacolooical Basis of Therapeutics, The Macmillian Company, New York Fourth Edition: 1300–1302, 1970.
10.
ShadomyS.: In Vitro Susceptibility of Cryptococcus Neoformans to Amphotericin B, Hanycin and 5-Fluorocytosine, Antimicrob. Agents Chemother.452–4601968.
11.
UtzJ.P.: 5-Fluorocytosine in Human Cryptococcosis, Antimicrob. Agents Chemother., 344–346, 1968.
12.
DewiesR. R., and ReevesD.S.: 5-Fluorocytosine and Urinary Candidiasis, Brit. Med. J.11: 577–579 (Jan. 30) 1971.
13.
MarksM.I.: In Vitro Sensitivity of Torulopsis Glabroto to Amphotericin B, 5-Fluorocytosine and Clotinazole, Applied Microbiol.22: 93–95, 1971.
14.
MarksM. I., and EickhoffI. T.: Application of Four Methods to the Study of the Susceptibility of Yeast to 5-Fluoroeytosine, Antimicrob. Agents Chemother.10: 491–493, 1970.
15.
MedoffG.: Potentiation of Rifampicin and 5-Fluorocytosine as Antifungal Antibiotics by Amphotericin B, Proc. Natl. Acad. Sci. USA69: 196–199, Jan. 1972.
16.
MedoffG.: Synergistic Action of Amphotericin B and 5-Fluorocytosine Against Yeast-like Organisms (35943), Proc. Soc. Exptl. Biol. Med.138: 571–574, 1971.
17.
KoechlinB.H.: The Metabolism of 5-Fluorocytosine-214C and of Cytosine-14C in the Rat and the Disposition of 5-Fluorocytosine-211C in Man, Biochem. Pharmacol.15: 435–446, 1966.
18.
SchönebeckJ.: Studies on Candida Infection of the Urinary Tract and on the Antimycotic Drug 5-Fluorocytosine, Scand. J. Urol. Nephrol. Suppl.11: 35–44, 1972.
19.
SteerP.: 5-Fluorocytosine: An Oral Antifungal Compound, Ann. Intern Med.76: 15–22 (Jan.) 1972.
20.
TasselD., and MadoffM. A.: Treatment of Candida Sepsis and Cryptococcus Meningitis with 5-Fluorocytosine, J. Am. Med. Ass.206: 830–832, 1968.
21.
WatkinsJ.S.: Two Cases of Cryptococcal Meningitis, One Treated with 5-Fluorocytosine, Brit. Med. J.2: 29–31, 1969.
22.
WebbA.J.: Torulopsis Glabrata Septicaemia Treated with 5-Fluorocytosine, Lancet1: 839–840, 1970.
